Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$3.87 USD
+0.27 (7.50%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $3.88 +0.01 (0.26%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FULC 3.87 +0.27(7.50%)
Will FULC be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for FULC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FULC
STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag
FULC: What are Zacks experts saying now?
Zacks Private Portfolio Services
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine
Other News for FULC
Leerink sees little impact to genetic medicines from Pfizer's Oxbryta withdrawal
Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher
Fulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setback
Fulcrum reduces its workforce
Largest borrow rate increases among liquid names